Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To assess whether the reduction of tumor burden is directly correlated with the reduction of all T-cell subsets during long-term treatment with the Bruton's tyrosine kinase inhibitor ibrutinib in relapsed or refractory chronic lymphocytic leukemia patients

Next Previous
Trial Profile

To assess whether the reduction of tumor burden is directly correlated with the reduction of all T-cell subsets during long-term treatment with the Bruton's tyrosine kinase inhibitor ibrutinib in relapsed or refractory chronic lymphocytic leukemia patients

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jan 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibrutinib (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Pharmacodynamics

Most Recent Events

  • 29 Jan 2019 New trial record
  • 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top